Lord, Abbett & Co
CERE

Lord, Abbett & Co’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Lord, Abbett & Co’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-332,597
Closed -$10.6M – 597
2023
Q2 		$10.6M Sell
332,597
-305
-0.1% -$9.36K 0.04% 413
2023
Q1 		$8.12M Sell
332,902
-788,664
-70% -$23.1M 0.03% 428
2022
Q4 		$35.4M Buy
1,121,566
+35,610
+3% +$1M 0.13% 235
2022
Q3 		$30.7M Buy
1,085,956
+82,992
+8% +$2.47M 0.11% 245
2022
Q2 		$26.5M Buy
1,002,964
+273,114
+37% +$7.75M 0.09% 286
2022
Q1 		$25.6M Buy
729,850
+685
+0.1% +$20K 0.07% 340
2021
Q4 		$23.6M Buy
+729,165
New +$25.7M 0.05% 374

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lord, Abbett & Co's CERE Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 332,597 shares — an estimated $10.6M sold.

Lord, Abbett & Co first reported a position in CERE in Q4 2021 and held it in 7 quarters. The position peaked at $35.4M in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 332,597 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $10.6M.
  • Lord, Abbett & Co first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Lord, Abbett & Co's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $35.4M in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.